Amneal

Bridgewater, United States Founded: 2002 • Age: 24 yrs
Manufacturer of generics formulations
Annual revenue $2.8B Latest available
Total funding - 3 rounds
Employees 8300 Tracked headcount
Investors 3 Known backers
Products 3 Services tracked
Competitors - Brand Intelligence

About Amneal

Amneal is a company based in Bridgewater (United States) founded in 2002. The company has 8,300 employees as of December 31, 2024. Amneal has completed 7 acquisitions, including AvKARE, Epsilon Pharmaceuticals and Gemini Laboratories. Amneal offers products and services including Generic Products, Specialty Products, and Biosciences Products.

  • Headquarter Bridgewater, United States
  • Employees 8300 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Amneal Pharmaceuticals, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $2.79 B (USD)
    16.73
    as on Dec 31, 2024
  • Net Profit
    -$116.89 M (USD)
    -39.16
    as on Dec 31, 2024
  • EBITDA
    $589.48 M (USD)
    19.71
    as on Dec 31, 2024
  • Latest Funding Round
    $19.2 M (USD), Post-IPO

    Nov 16, 2018

  • Investors
  • Employee Count
    8300

    as on Dec 31, 2024

  • Investments & Acquisitions
    AvKARE

    & 6 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Amneal

Amneal is a publicly listed company on the NASDAQ with ticker symbol AMRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: AMRX · Sector: Health technology · USA

Products & Services of Amneal

Amneal offers a comprehensive portfolio of products and services, including Generic Products, Specialty Products, and Biosciences Products.

Product name locked
Category locked
Primary

Essential generic medicines for treating various common health conditions

Product name locked
Category locked
Locked

Innovative drugs for specific diseases like Parkinson's and oncology

Product name locked
Category locked
Locked

Advanced biosimilars for institutional and patient use worldwide

People of Amneal

Headcount 1000-5000
Employee Profiles 128
Board Members and Advisors 9
Employee Profiles
People
Sarah Klein
Director, Corporate Counsel - Litigation
People
Ca Nidhi Trivedi
Internal Audit Manager
People
Luke Haley Phr
Senior Human Resources Manager
People
Robert Miranda
Director, Revenue Accounting

Unlock access to complete

Board Members and Advisors
people
Jeff George
Director
people
Shlomo Yanai
Director
people
Emily Peterson Alva
Director
people
John Kiely
Director

Unlock access to complete

Funding Insights of Amneal

Investors in Amneal

Amneal has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Northern Trust, GE Capital and Tarsadia.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital and private equity are directed toward multiple sectors.
Locked Locked Locked
Financial and wealth management services are provided worldwide.
Locked Locked Locked
Commercial aircraft and equipment leasing and lending services are provided.
Locked Locked Locked
Premium access

Investor details for Amneal

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Amneal

Amneal has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include AvKARE, Epsilon Pharmaceuticals and Gemini Laboratories.

Investments
Premium access

Investment portfolio details for Amneal

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Therapeutic solutions for rare diseases are developed.
Locked Locked 2020 Locked
Therapeutic products are developed and manufactured by Puniska.
Locked Locked 2017 Locked
Science-based nutrition products are developed for infants, children, and adults.
Locked Locked 2013 Locked
Premium access

Complete acquisition details for Amneal

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Amneal

Premium access

Detailed financials for Amneal

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Amneal Comparisons

Amneal Primary company
Description
Manufacturer of generics formulations
Location
Bridgewater, United States
Founded Year
2002
Annual Revenue
$2.79 B (USD)
Net Profit
-$116.89 M (USD)
EBITDA
$589.48 M (USD)
Employees
8,300
As of 2024
Premium access

Peer comparison for Amneal

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Amneal

Premium access

Detailed competitors of Amneal

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Amneal

Premium access

Complete news archive for Amneal

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amneal

Amneal was founded in 2002 and raised its 1st funding round 3 years after it was founded.

Amneal is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.

As of Dec 31, 2024, the latest employee count at Amneal is 8,300.

Annual revenue of Amneal is $2.79B as on Dec 31, 2024.

Amneal Pharmaceuticals is a fully-integrated pharmaceutical company focused on the development, manufacture, and distribution of generic and specialty drug products. The company has an extensive portfolio of approximately 250 generic medicines and is expanding its portfolio to include complex dosage forms including biosimilars in a broad range of therapeutic areas. The company also markets a portfolio of branded pharmaceutical products through its specialty segment focused principally on the central nervous system and endocrine disorders.

Amneal offers Generic Products, Specialty Products, and Biosciences Products.

Yes, Amneal is publicly traded on NASDAQ under the ticker symbol AMRX.

Amneal has made 7 acquisitions, including AvKARE, Epsilon Pharmaceuticals, and Gemini Laboratories.

Amneal has 3 investors. Key investors include Northern Trust, GE Capital, and Tarsadia.

The ticker symbol of Amneal is AMRX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available